Conference Correspondent
News, views, and coverage of important topics and discussions from oncology conferences and events.
CPX-351 plus 7 days of venetoclax was tolerable and demonstrated encouraging activity in patients with relapsed/refractory acute myeloid leukemia.
Read More ›
An escalated 21-day CC-486 (oral azacitidine) dosing regimen was well-tolerated and restored remission in approximately 25% of patients with acute myeloid leukemia (AML) who relapsed with 5% to 15% blasts on-study in the QUAZAR AML-001 trial. Read More ›
Among patients with relapsed/refractory acute myeloid leukemia (R/R AML), patient-specific doses of iodine-131-apamistamab resulted in consistent engraftment following allogeneic hematopoietic stem-cell transplantation. Read More ›
Across multiple acute myeloid leukemia (AML) subgroups, venetoclax + FLAG-IDA was effective, elicited deep responses, and had an acceptable safety profile, representing an attractive option as a bridge to allo-SCT for adverse-risk, newly diagnosed, and relapsed/refractory (R/R) AML patients. Read More ›
Overall survival hazard ratios based on adjusted simulated treatment comparisons numerically, but not statistically, favored glasdegib plus low-dose cytarabine (LDAC) over venetoclax plus LDAC. Read More ›
In older patients with de novo acute myeloid leukemia, the combination of selinexor with standard induction and consolidation therapy appears highly active. Read More ›
In patients with newly diagnosed IDH2mut acute myeloid leukemia (AML), treatment with enasidenib was associated with low early death and high complete response and complete response with incomplete hematologic recovery rates and yielded durable remission.
Read More ›
As salvage therapy in younger patients with relapsed/refractory acute myeloid leukemia (AML), the efficacy of 10-day decitabine + venetoclax is comparable to intensive chemotherapy regimens and is an appropriate bridge to allogeneic stem-cell transplantation. Read More ›
Survival outcomes are not worse for patients with endothelial ovarian cancer treated with neoadjuvant chemotherapy if cytoreduction surgery is delayed beyond 3 cycles of treatment. Read More ›
Niraparib improved progression-free survival when used as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer with BRCA wild-type tumors, regardless of homologous recombination status. Read More ›